Cargando…
Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans
BACKGROUND: Given the paucity of information on dose intensity, the objective of this study is to describe the use of adjuvant chemotherapy for stage III colon cancer, focusing on relative dose intensity (RDI), overall survival (OS) and disease-free survival (DFS). METHODS: Retrospective cohort of 3...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352567/ https://www.ncbi.nlm.nih.gov/pubmed/25884851 http://dx.doi.org/10.1186/s12885-015-1038-y |
_version_ | 1782360481558691840 |
---|---|
author | Aspinall, Sherrie L Good, Chester B Zhao, Xinhua Cunningham, Francesca E Heron, Bernadette B Geraci, Mark Passero, Vida Stone, Roslyn A Smith, Kenneth J Rogers, Renee Shields, Jenna Sartore, Megan Boyle, D Patrick Giberti, Sherry Szymanski, John Smith, Doug Ha, Allen Sessions, Jolynn Depcinski, Shawn Fishco, Shane Molina, Irvin Lepir, Tanja Jean, Carmela Cruz-Diaz, Lymaris Motta, Jessica Calderon-Vargas, Rebeca Maland, Janelle Keefe, Sean Tague, Marshall Leone, Alice Glovack, Brian Kaplan, Blair Cosgriff, Sean Kaster, Lindsay Tonnu-Mihara, Ivy Nguyen, Kimmai Carmichael, Jenna Clifford, Linda Lu, Kan Chatta, Gurkamal |
author_facet | Aspinall, Sherrie L Good, Chester B Zhao, Xinhua Cunningham, Francesca E Heron, Bernadette B Geraci, Mark Passero, Vida Stone, Roslyn A Smith, Kenneth J Rogers, Renee Shields, Jenna Sartore, Megan Boyle, D Patrick Giberti, Sherry Szymanski, John Smith, Doug Ha, Allen Sessions, Jolynn Depcinski, Shawn Fishco, Shane Molina, Irvin Lepir, Tanja Jean, Carmela Cruz-Diaz, Lymaris Motta, Jessica Calderon-Vargas, Rebeca Maland, Janelle Keefe, Sean Tague, Marshall Leone, Alice Glovack, Brian Kaplan, Blair Cosgriff, Sean Kaster, Lindsay Tonnu-Mihara, Ivy Nguyen, Kimmai Carmichael, Jenna Clifford, Linda Lu, Kan Chatta, Gurkamal |
author_sort | Aspinall, Sherrie L |
collection | PubMed |
description | BACKGROUND: Given the paucity of information on dose intensity, the objective of this study is to describe the use of adjuvant chemotherapy for stage III colon cancer, focusing on relative dose intensity (RDI), overall survival (OS) and disease-free survival (DFS). METHODS: Retrospective cohort of 367 patients diagnosed with stage III colon cancer in 2003–2008 and treated at 19 VA medical centers. Kaplan-Meier curves summarize 5-year OS and 3-year DFS by chemotherapy regimen and RDI, and multivariable Cox proportional hazards regression was used to model these associations. RESULTS: 5-fluorouracil/leucovorin (FU/LV) was the most commonly initiated regimen in 2003 (94.4%) and 2004 (62.7%); in 2005–2008, a majority of patients (60%-74%) was started on an oxaliplatin-based regimen. Median RDI was 82.3%. Receipt of >70% RDI was associated with better 5-year OS (p < 0.001) and 3-year DFS (P = 0.009) than was receipt of ≤70% RDI, with 5-year OS rates of 66.3% and 50.5%, respectively and 3-year DFS rates of 66.1% and 52.7%, respectively. In the multivariable analysis of 5-year OS, oxaliplatin + 5-FU/LV (versus 5-FU/LV) (HR = 0.55; 95% CI = 0.34-0.91), >70% RDI at the first year (HR = 0.58; 95% CI = 0.37-0.89) and married status (HR = 0.66; 95% CI = 0.45-0.97) were associated with significantly decreased risk of death, while age ≥75 (versus 55–64) (HR = 2.06; 95% CI = 1.25-3.40), Charlson Comorbidity Index (HR = 1.17; 95% CI = 1.06-1.30), T4 tumor status (versus T1/T2) (HR = 5.88; 95% CI = 2.69-12.9), N2 node status (HR = 1.68; 95% CI = 1.12-2.50) and bowel obstruction (HR = 2.32, 95% CI = 1.36-3.95) were associated with significantly increased risk. Similar associations were observed for DFS. CONCLUSION: Patients with stage III colon cancer who received >70% RDI had improved 5-year OS. The association between RDI and survival needs to be examined in studies of adjuvant chemotherapy for colon cancer outside of the VA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1038-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4352567 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43525672015-03-09 Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans Aspinall, Sherrie L Good, Chester B Zhao, Xinhua Cunningham, Francesca E Heron, Bernadette B Geraci, Mark Passero, Vida Stone, Roslyn A Smith, Kenneth J Rogers, Renee Shields, Jenna Sartore, Megan Boyle, D Patrick Giberti, Sherry Szymanski, John Smith, Doug Ha, Allen Sessions, Jolynn Depcinski, Shawn Fishco, Shane Molina, Irvin Lepir, Tanja Jean, Carmela Cruz-Diaz, Lymaris Motta, Jessica Calderon-Vargas, Rebeca Maland, Janelle Keefe, Sean Tague, Marshall Leone, Alice Glovack, Brian Kaplan, Blair Cosgriff, Sean Kaster, Lindsay Tonnu-Mihara, Ivy Nguyen, Kimmai Carmichael, Jenna Clifford, Linda Lu, Kan Chatta, Gurkamal BMC Cancer Research Article BACKGROUND: Given the paucity of information on dose intensity, the objective of this study is to describe the use of adjuvant chemotherapy for stage III colon cancer, focusing on relative dose intensity (RDI), overall survival (OS) and disease-free survival (DFS). METHODS: Retrospective cohort of 367 patients diagnosed with stage III colon cancer in 2003–2008 and treated at 19 VA medical centers. Kaplan-Meier curves summarize 5-year OS and 3-year DFS by chemotherapy regimen and RDI, and multivariable Cox proportional hazards regression was used to model these associations. RESULTS: 5-fluorouracil/leucovorin (FU/LV) was the most commonly initiated regimen in 2003 (94.4%) and 2004 (62.7%); in 2005–2008, a majority of patients (60%-74%) was started on an oxaliplatin-based regimen. Median RDI was 82.3%. Receipt of >70% RDI was associated with better 5-year OS (p < 0.001) and 3-year DFS (P = 0.009) than was receipt of ≤70% RDI, with 5-year OS rates of 66.3% and 50.5%, respectively and 3-year DFS rates of 66.1% and 52.7%, respectively. In the multivariable analysis of 5-year OS, oxaliplatin + 5-FU/LV (versus 5-FU/LV) (HR = 0.55; 95% CI = 0.34-0.91), >70% RDI at the first year (HR = 0.58; 95% CI = 0.37-0.89) and married status (HR = 0.66; 95% CI = 0.45-0.97) were associated with significantly decreased risk of death, while age ≥75 (versus 55–64) (HR = 2.06; 95% CI = 1.25-3.40), Charlson Comorbidity Index (HR = 1.17; 95% CI = 1.06-1.30), T4 tumor status (versus T1/T2) (HR = 5.88; 95% CI = 2.69-12.9), N2 node status (HR = 1.68; 95% CI = 1.12-2.50) and bowel obstruction (HR = 2.32, 95% CI = 1.36-3.95) were associated with significantly increased risk. Similar associations were observed for DFS. CONCLUSION: Patients with stage III colon cancer who received >70% RDI had improved 5-year OS. The association between RDI and survival needs to be examined in studies of adjuvant chemotherapy for colon cancer outside of the VA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1038-y) contains supplementary material, which is available to authorized users. BioMed Central 2015-02-18 /pmc/articles/PMC4352567/ /pubmed/25884851 http://dx.doi.org/10.1186/s12885-015-1038-y Text en © Aspinall et al.; licensee BioMed Central. 2015 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Aspinall, Sherrie L Good, Chester B Zhao, Xinhua Cunningham, Francesca E Heron, Bernadette B Geraci, Mark Passero, Vida Stone, Roslyn A Smith, Kenneth J Rogers, Renee Shields, Jenna Sartore, Megan Boyle, D Patrick Giberti, Sherry Szymanski, John Smith, Doug Ha, Allen Sessions, Jolynn Depcinski, Shawn Fishco, Shane Molina, Irvin Lepir, Tanja Jean, Carmela Cruz-Diaz, Lymaris Motta, Jessica Calderon-Vargas, Rebeca Maland, Janelle Keefe, Sean Tague, Marshall Leone, Alice Glovack, Brian Kaplan, Blair Cosgriff, Sean Kaster, Lindsay Tonnu-Mihara, Ivy Nguyen, Kimmai Carmichael, Jenna Clifford, Linda Lu, Kan Chatta, Gurkamal Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans |
title | Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans |
title_full | Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans |
title_fullStr | Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans |
title_full_unstemmed | Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans |
title_short | Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans |
title_sort | adjuvant chemotherapy for stage iii colon cancer: relative dose intensity and survival among veterans |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352567/ https://www.ncbi.nlm.nih.gov/pubmed/25884851 http://dx.doi.org/10.1186/s12885-015-1038-y |
work_keys_str_mv | AT aspinallsherriel adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT goodchesterb adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT zhaoxinhua adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT cunninghamfrancescae adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT heronbernadetteb adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT geracimark adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT passerovida adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT stoneroslyna adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT smithkennethj adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT rogersrenee adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT shieldsjenna adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT sartoremegan adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT boyledpatrick adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT gibertisherry adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT szymanskijohn adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT smithdoug adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT haallen adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT sessionsjolynn adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT depcinskishawn adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT fishcoshane adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT molinairvin adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT lepirtanja adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT jeancarmela adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT cruzdiazlymaris adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT mottajessica adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT calderonvargasrebeca adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT malandjanelle adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT keefesean adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT taguemarshall adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT leonealice adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT glovackbrian adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT kaplanblair adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT cosgriffsean adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT kasterlindsay adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT tonnumiharaivy adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT nguyenkimmai adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT carmichaeljenna adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT cliffordlinda adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT lukan adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans AT chattagurkamal adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans |